Sign in

You're signed outSign in or to get full access.

ET

Eterna Therapeutics Inc. (ERNA)·Q2 2021 Earnings Summary

Executive Summary

  • Q2 2021 was a transitional quarter as the company shifted from a cytokine-focused model toward a broader gene editing and cell therapy platform, highlighted by closing the Novellus acquisition in July and establishing a Cambridge R&D center to advance mRNA-based cell reprogramming and gene editing technologies .
  • Operating expenses rose sharply YoY on licensing up-fronts, clinical spend, and public-company costs; R&D was $5.4M vs. $1.0M YoY and G&A was $4.6M vs. $1.0M YoY. Net loss for the quarter per the financial statements was $10.1M (EPS $(0.24)), while a narrative line in the release referenced $(27.8)M which corresponds to the six-month period—an important disclosure discrepancy to note .
  • Liquidity strengthened: cash and equivalents were $50.2M at 6/30/21; management said cash after the Novellus deal (approx. $25M) would fund operations and expansion through end of 2023, following ~$51M raised from an equity line earlier in 2021 .
  • Near-term catalyst: top-line readout of INSPIRE (Phase 2b HNSCC) expected in H1 2022, plus platform development updates tied to the licensed mRNA gene-editing/cell reprogramming programs .

What Went Well and What Went Wrong

  • What Went Well

    • Platform expansion progressed: closed the Novellus acquisition and co-located a new Cambridge R&D center to accelerate mRNA-based reprogramming and gene editing programs .
    • Strengthened balance sheet: raised nearly $51M via equity sales, contributing to $50.2M of cash at quarter-end; post-acquisition cash of ~ $25M targeted to fund operations through end of 2023 .
    • Strategic hiring: appointed a new Chief Scientific Officer (Kevin D’Amour, Ph.D.) and Chief Administrative Officer (Jay Sial) to support platform ambitions .

  • What Went Wrong

    • Expense intensity increased: R&D rose to $5.4M on licensing payments, clinical costs, and stock comp; G&A rose to $4.6M on M&A-related professional fees and public company costs; total opex up to $10.1M .
    • Disclosure inconsistency: the press release text cited Q2 net loss at $(27.8)M, but the financial statements show Q2 net loss of $(10.1)M and $(27.8)M for the six-month period—investors should anchor to the financial tables .
    • No product revenue and continued operating losses; the company signaled R&D and G&A should continue to increase as clinical and corporate activities expand .

Financial Results

MetricQ2 2020Q1 2021Q2 2021
Revenues ($M)$0.0 $0.0 $0.0
R&D Expense ($M)$1.0 $1.52 $5.39
G&A Expense ($M)$1.03 $1.64 $4.62
Total Operating Expenses ($M)$2.02 $8.10 $10.01
Loss from Operations ($M)$(2.02) $(8.10) $(10.01)
Net Loss ($M)$(2.03) $(17.70) $(10.09)
Diluted EPS ($)$(0.12) $(0.64) $(0.24)
Cash & Equivalents (period-end, $M)$5.19 $8.41 $50.16

Notes:

  • The $27.8M net loss line referenced in the release text corresponds to the six months ended June 30, 2021; the quarter’s net loss was ~$10.1M per the financial statements (EPS $(0.24)) .
  • Company had no reported product revenue in the periods shown .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash runwayThrough end of 2023N/A“Following the Novellus acquisition, we had approximately $25M of cash on hand, which we estimate will fund our operations and expansion through the end of 2023.” New
INSPIRE (HNSCC) topline timingH1 2022“Top-line data estimated to be available in H1 2022.” (communicated prior quarter) Reiterated H1 2022 timing Maintained
R&D expense trajectory2H21+N/A“Expects R&D expenses to continue to grow as it expands its clinical trial activities.” Established
G&A expense trajectory2H21+N/A“Expects G&A expenses to continue to increase as it increases business activities and incurs public company costs.” Established

Earnings Call Themes & Trends

Note: We did not find a Q2 2021 earnings call transcript for the company. A later “shareholder update call” was held in September 2021 (not part of Q2 reporting) .

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q2 2021)Trend
Platform expansion (mRNA reprogramming/gene editing)Executed exclusive license with Factor/Novellus on Apr 26, 2021 to develop cell-based therapies; milestone structure detailed in 10-Q Closed acquisition of Novellus in July; positioned to create a platform for engineered cellular, gene editing, and cytokine products Accelerating
Financing/liquidityEntered $20M Lincoln Park purchase agreement; $6.3M raised through May 14, 2021 Raised nearly $51M via equity line; cash $50.2M at 6/30/21; estimated runway through end of 2023 (post-acquisition cash ~ $25M) Improving liquidity
R&D execution (INSPIRE and preclinical)INSPIRE fully populated; H1’22 topline expected; multiple investigator-led combination trials ongoing Awaiting INSPIRE readout H1’22; adding programs in respiratory and preclinical pipeline under new platform On track
COVID-19 operational impactPrior quarter warned of enrollment slowdowns and site close-out delays, particularly for INSPIRE No new COVID-19 update in the Q2 release; prior risk disclosures remain relevant Persistent risk
Organization buildCEO/President appointed Apr 2021; stock option grants and governance updates detailed Hired CSO and CAO; established Cambridge R&D site co-located with Factor Scaling capabilities

Management Commentary

  • “The second quarter advanced the evolution of Brooklyn ImmunoTherapeutics from being a cytokine-focused immunotherapeutics company to a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine products.” – Howard J. Federoff, M.D., Ph.D., CEO .
  • “By combining [Novellus’ MSCs] with our licensed mRNA-based cell reprogramming and gene editing technology from Factor Bioscience, we believe we can create a platform technology that will lead to a family of product candidates in varying stages of development...” .
  • “Following the Novellus acquisition, we had approximately $25 million of cash on hand, which we estimate will fund our operations and expansion through the end of 2023.” .

Q&A Highlights

  • We found no Q2 2021 earnings call or transcript; the company furnished results via an 8-K press release. A separate “shareholder update call” occurred on Sept 20, 2021 (after Q2), with highlights published thereafter .

Estimates Context

  • We attempted to retrieve S&P Global consensus for Q2 2021 (Revenue and EPS) but data were unavailable at the time of this analysis; therefore, no beat/miss assessment vs. Wall Street estimates is included.

Key Takeaways for Investors

  • The story is shifting from single-asset cytokine therapy to a broader gene editing/cell therapy platform with the Novellus acquisition and Cambridge R&D build-out—this broadens optionality beyond the HNSCC readout .
  • Liquidity improved markedly (cash $50.2M at quarter-end); management targeted runway through end of 2023 post-deal, reducing near-term financing overhang while enabling platform investments .
  • Expense growth will continue near term as programs and corporate infrastructure scale; investors should expect R&D and G&A to trend higher from Q2 levels .
  • Key 6–12 month catalyst: INSPIRE Phase 2b HNSCC topline in H1 2022; positive data could be a material re-rating event and strategic optionality inflection .
  • Watch execution on platform integration and preclinical pipeline advancement (respiratory, solid tumors, in vivo gene-editing for rare diseases) for evidence the platform thesis is taking hold .
  • Note disclosure rigor: rely on the financial tables for net loss (Q2 $(10.1)M) rather than the narrative $(27.8)M figure, which corresponds to six-month results .

Sources:

  • ERNA (then Brooklyn ImmunoTherapeutics, BTX) Q2 2021 8-K and press release with full financials .
  • Q1 2021 10-Q for prior-quarter benchmarks, license, liquidity, and operational risk disclosures .
  • No Q2 2021 earnings call transcript located; later shareholder update call press coverage (Sept 2021) .